Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the glycemic variations during acute coronary syndrome in non-diabetic patients (euglycemic, or with impaired fasting glucose, or with impaired glucose tolerance)
All nondiabetic patients with dysglycemia (fasting plasma glucose between 100 and 125 mg/dl) will be monitored with a device (Continuous Glucose Monitoring System) and all these patients will be undergone an oral glucose tolerance test after the discharge from this Unit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dysglycemic group | Experimental | Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient. Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Continuous Glucose Monitoring System (i Pro 2 - Medtronic) | Device | This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device. |
| Measure | Description | Time Frame |
|---|---|---|
| Glycemic status | Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient. Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus. | 15 days |
| Measure | Description | Time Frame |
|---|---|---|
| Lipid profile | Total cholesterol | 15 days |
| Lipid profile | HDL-cholesterol | 15 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Giuseppe Derosa, MD, PhD, FESC | University of Pavia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Giuseppe Derosa | Pavia | 27100 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054058 | Acute Coronary Syndrome |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000095583 | Continuous Glucose Monitoring |
| ID | Term |
|---|---|
| D001774 | Blood Chemical Analysis |
| D019963 | Clinical Chemistry Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
Not provided
Not provided
CGMS
Not provided
Not provided
CGMS
Not provided
| Lipid profile | Triglycerides | 15 days |
| Lipid profile | Lipoprotein (a) | 15 days |
| Endothelial damage | sICAM-1 | 15 days |
| Endothelial damage | sVCAM-1 | 15 days |
| Inflammation parameters | sRAGE | 15 days |
| Inflammation parameters | sCD40L | 15 days |
| Inflammation parameters | MPO | 15 days |
| Inflammation parameters | hs-CRP | 15 days |
| Inflammation parameters | IL-6 | 15 days |
| Inflammation parameters | TNF-alfa | 15 days |
| Heart damage | CPK | 15 days |
| Heart damage | I troponin | 15 days |
| D003933 | Diagnosis |
| D003940 | Diagnostic Techniques, Endocrine |
| D008991 | Monitoring, Physiologic |
| D008919 | Investigative Techniques |